Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176010 | PMC |
| http://dx.doi.org/10.1002/jha2.78 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
SOHO State of the Art Updates and Next Questions | Venetoclax + Obinutuzumab Therapy in Chronic Lymphocytic Leukemia.
Clin Lymphoma Myeloma Leuk
December 2024
Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY.
In the past decade, the treatment paradigm for chronic lymphocytic leukemia (CLL) has markedly shifted from traditional chemoimmunotherapy towards targeted therapies. A fixed-duration, targeted regimen with venetoclax, a potent oral BCL-2 inhibitor, combined with obinutuzumab, a glycoengineered type II anti-CD20 monoclonal antibody (Ven-Obi), has become the standard to beat for time-limited therapy in CLL. Ven-Obi allows for the rapid induction of remissions with high rates of undetectable minimal residual disease (uMRD) in patients across different treatment settings.
View Article and Find Full Text PDFA phase I trial of CC-486, lenalidomide, obinutuzumab in relapsed/refractory indolent non-Hodgkin lymphoma.
Leuk Lymphoma
December 2024
Department of Internal Medicine, Division of Malignant Hematology/Cellular Therapy and Transplantation, University of California Davis School of Medicine, Sacramento, CA, USA.
Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström's macroglobulinemia.
Ann Hematol
November 2024
Hematology Department, Hôpital Pitié Salpêtrière APHP, Sorbonne University, Paris, France.
We present the 6-year update of a phase 2 study evaluating the combination of obinutuzumab and idelalisib in relapse/refractory Waldenstrom macroglobulinemia. The results of the REMODEL trial demonstrated interesting efficacy in a high-risk genotype profile population. The primary endpoint was achieved with a median PFS of 25.
View Article and Find Full Text PDFObinutuzumab as a viable therapeutic strategy in rituximab-refractory childhood frequently relapsing, steroid-dependent nephrotic syndrome that relapsed during B-cell depletion.
Pediatr Nephrol
October 2024
Paediatric Nephrology Centre, Hong Kong Children's Hospital, Kowloon, Hong Kong SAR.
A subgroup of children with frequently-relapsing, steroid-dependent nephrotic syndrome relapse during B-cell depletion after rituximab. A 15-year-old boy with focal segmental glomerulosclerosis became rituximab-refractory after 5 courses of treatments, with a relapse-free period shortened to 1 month. Circulating total and memory B-cells were undetectable at the time of relapse.
View Article and Find Full Text PDFObinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy.
Nephrol Dial Transplant
October 2024
Division of Nephrology, Huashan Hospital, Fudan University, Shanghai, China.
Article Synopsis
- Rituximab is effective for treating primary membranous nephropathy but has limited response rates; obinutuzumab, a stronger B-cell depleting antibody, may show better outcomes.
- A study at Huashan Hospital compared the effectiveness of obinutuzumab and rituximab in adult patients resistant to traditional treatments from 2015 to 2024, focusing on overall remission and safety.
- Results revealed a much higher response rate for obinutuzumab (90%) compared to rituximab (38.7%), along with better immunological remission rates, while both treatments had similar safety profiles.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!